Amneal to Participate at Upcoming Investor Conferences in May
Amneal to Participate at Upcoming Investor Conferences in May
Amneal Pharmaceuticals (NYSE: AMRX) will participate in several investor conferences, including the RBC Healthcare Conference on May 17, 2022, and the UBS Healthcare Conference on May 25, 2022, both in New York City.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its investor relations or management team will attend the following investor conferences:
RBC Healthcare Conference May 17, 2022 Investor Relations Hosted Meetings
New York, New York
UBS Healthcare Conference May 25, 2022 Investor Relations Hosted Meetings
New York, New York
Barclays CEO Call Series
May 27, 2022 Fireside Chat – 10:00am Eastern Time
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.
